Whilst researchers look for biomarkers to forecast ketamine reaction, clinicians discover themselves with a conundrum: Which patients really should start with IV ketamine, and which with Spravato? And just how do the two compare head to head in precise response to treatment? Patients have a substantial advancement in pain. Patients https://bruceq888lzn5.wikiadvocate.com/user